LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Towards an accurate accounting for carbon from biomass in the Product Environmental Footprint (PEF)

29/07/2022
POSITION PAPER
Bio-based products are products wholly or partly derived from renewable materials of biological origin (i.e. from plants, crops, trees, algae and biological waste). These products are used in a wide range of applications, such as energy, textile, plastics, pharmaceuticals, hygiene, food and many more.

We need a fairer method to account for the footprint of biogenic carbon and allocate it to the actors along the bioeconomy value chains.

Biogenic carbon in the current PEF rules
In the currently proposed methodology of the Product Environmental Footprint rules addressing biogenic carbon, there is no recognized benefit granted to the producers of biomass-derived products, compared to fossil ones.

In a cradle-to-grave approach, the biogenic uptake and emissions of CO2 from disposal are balanced. Therefore, in such a cradle-to-grave approach, biomass derived products will not receive any CO2 burden when they are disposed of, while fossil products will receive a CO2 burden in case of incineration.

However, in a cradle-to-gate life-cycle analysis using PEF methodology, biomass-derived products will not receive any credit for the fact that CO2 was removed from the atmosphere during photosynthesis and plant growth. Whereas in LCA (ISO 14067, EN 15804 and other LCA standards1) biogenic CO2 uptake in biomass-derived products shall be addressed.

When the use of the product cannot be singled out - like platform chemicals which are used for a range of different other products or intermediates -, the manufacturers need to supply a cradle-to-gate LCA. Accordingly, there will be no CO2 credit for bio-based raw materials calculated at the gate of the product. It will look like there is hardly any benefit from producing biomass-derived products if any at all, compared to fossil based.

The same “accounting” problem appears when biomass feedstock is blended with fossil feedstock, like in mass balance scenarios. There will hardly be any difference in greenhouse gas footprints as long as a cradle-to-gate assessment is used for life-cycle inventories and for full LCA where other forms of end-of life approaches than incineration are applied. Additionally with the current approach, the use of the products in long-lasting applications, investment goods and others are not considered as an actual removal of biogenic CO2.

Read the full position here.

Towards an accurate accounting for carbon from biomass in the Product Environmental Footprint (PEF)


Download
Share
Communications Team
Communications Team

Related posts

14/11/2025

Vial joins EuropaBio: Reimagining Drug Development with Hyper-Scalable Biotech


Read more
12/11/2025

EuropaBio response to the EU Biotech Act public consultation


Read more
05/11/2025

EuropaBio recommendations for the Circular Economy Act


Read more

Important links

  • Vial joins EuropaBio: Reimagining Drug Development with Hyper-Scalable Biotech
  • EuropaBio response to the EU Biotech Act public consultation

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.